Introduction
Chronic kidney disease (CKD) is an emerging public health problem that affects 5-10% of the world population, with adverse outcomes due to the progressive loss of kidney function, cardiovascular disease (CVD) and premature death. 1 The patients with CKD constitute a major economic burden both directly in terms of resource utilization and indirectly in terms of loss of productivity and impaired quality of life. With availability of recent treatment modalities including renal replacement therapy, the survival of CKD patients have increased considerably which has led to an increased focus on health-related quality of life (HRQoL) as an integral part of evaluating treatment effectiveness and assessing health outcomes of these patients. HRQoL, like subjective health status, is patient based, but focuses more on the impact of a perceived health state on the ability to live a fulfilling life. It is a multi-dimensional concept incorporating social, psychological and physical health. 2 World Health Organization Quality of Life Group has provided a definition of quality of life which takes into account individuals perception and his/her relationship to the environment. It is defined as an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. 3 HRQoL assumes an increasing importance as a marker of treatment quality in many chronic diseases. 4 Its evaluation allows the quantification of the disease consequences according to the patient's subjective perception and enables adjustment of medical decisions to their physical, emotional and social needs. Within chronic disease care, enhancing or maintaining HRQoL is an important goal. In the progressive course of CKD, the individual's ability to manage the disease already in earlier stages has gained increased attention However, only limited information is currently available regarding estimates of the relative impact of renal dysfunction on HRQoL and predictors of HRQoL as targets of intervention. Studying the extent to which psychosocial factors influence the QoL of patients with end stage renal disease (ESRD) is critical in identifying risk and protective factors that can be the target of intervention programs to improve QoL. Therefore, a study to assess relationship between renal function, HRQoL measures and its predictors will contribute in developing a comprehensive public health strategy. The various preventable and influencing factors affecting HRQoL in CKD patients if assessed early can be taken care for better management of CKD patients. The 36-item Short-Form health survey (SF36) has been validated as an effective tool to assess HRQoL in CKD patients. There have been only few studies which have evaluated HRQoL patterns and its predictors in different stages of CKD. Literature is silent about various factors influencing the quality of life across all stages in CKD patients. The objective of this study was to evaluate HRQoL in patients with different stages of CKD and to evaluate possible correlating and influencing factors affecting it, in a developing nation like India.
Materials and methods
In this cross-sectional study conducted at PGIMS Rohtak, India, 200 adults patients in CKD of stages 1-5 were assessed for HRQoL through the 36-item short-form (SF-36) questionnaire. Study was approved by ethical committee and PG board of studies, university of health sciences, Rohtak. All participants had given their informed consent. Patients with age less than 18 or more than 80 years, pregnant females, having psychiatric illness or cognitive dysfunction, transplanted kidney were excluded from study. In addition patient with conditions like drug abuse, and malignancy were also excluded. A total of 221 adult CKD patients were enrolled. Twelve patients with incomplete biochemical evaluation and nine patients refusing to give the consent were excluded from the study. Patients were divided into four groups according to their estimated Glomerular Filtration Rate (eGFR); group A-CKD 1-2, with GFR range > 90 ml/ min/1. The patients from all groups were asked to complete the SF-36 in connection with their visits at the nephrology clinic. Nephrology consultants and senior residents providing nephrology care in the hospital conducted the evaluation. Biomarkers for all participants were clinical history, blood pressure, weight and Body Mass Index (BMI) and blood test analyses. Blood test analyses were hemoglobin (Hb), total leucocyte count (TLC), urea, creatinine, uric acid, sodium, potassium, sugar, calcium, phosphate, erythrocyte sedimentation rate (ESR) and Creactive protein (CRP). Moreover, GFR was estimated using the Modification of Diet in Renal Disease formula in all participants. 5 Blood pressure was measured in horizontal or sitting position and mean arterial pressure (MAP) was calculated. Weight measures were performed and BMI was calculated. The SF-36 questionnaire is a self-administered general HRQoL questionnaire, not specific to any disease or treatment group. 6 The SF-36 is covered by a conceptual model of HRQoL 
Results
Out of total 200 patients, 112 were male and 88 were female. The mean age of patients was 49 years ranging from 18 to 80 years. The most common cause of CKD was Diabetes mellitus (30.5%) followed by hypertension (24%), Chronic glomerulonephritis (20.5%) and nephrotic syndrome (12.5%). Less frequent etiologies included obstructive uropathy, adult polycystic kidney disease and miscellaneous. Demographic and laboratory characteristics of patients are presented in Table 1 . All biomarkers showed a significant difference (P 0.01) across the CKD stages except MAP and BMI. CVD was significantly more frequent in CKD 4 and 5 than in CKD 1-3. As shown in Table 2 , the HRQoL scores in all dimensions impaired progressively and significantly (P < 0.001) across renal function levels and CKD stages. The mean PCS scores in group A, B, C and D were 49.62 6 5.94, 40.14 6 5.22, 35.39 6 5.36 and 29.13 6 7.71, respectively. A statistically significant decreasing trend in PCS scores was found in patients from group A to D (P < 0.001). The MCS scores also showed a statistically significant decreasing trend from group A to D (P < 0.001). The mean MCS scores were found to be 52.09 6 2.45 in group A, 39.67 6 11.70 in group B, 35.66 6 5.97 in group C and 29.13 6 7.71 in group D. Large differences between CKD stages were seen in in all HRQoL dimensions including composite scores. The patients in CKD 1-3 (group A and B) had significantly lower scores on all HRQoL dimensions than patients in CKD 4-5 (group C and D).
Categorized correlates (GFR, age, gender, diabetes, history of CVD, Hb, ESR, CRP, MAP, BMI) and PCS, MCS scores are shown in Table 3 . eGFR < 30 ml/min/1.73 m 2 as well as CRP ! 5 mg/l, Hb 90 g/l, ESR ! 20 mm at first hour and MAP ! 100 mm hg had significantly lower scores on all HRQoL dimensions. Among those with CVD, the PCS, MCS and all subscales were significantly lower than in those with no history of CVD (P < 0.01). In those with diabetes, PCS, MCS and 'physical functioning', 'role physical' and 'role emotional' were significantly lower compared with those without diabetes (P < 0.05). The group aged ! 50 years showed lower scores on PCS, MCS and all subscales than the younger group, all at a significant level (P < 0.05). BMI did not affect HRQoL significantly. Females had significant lower PCS scores compared with males (P < 0.05), however no difference in MCS scores was observed. A Pearson's correlation was applied to determine the relationship between continuous variables and HRQoL scores. As depicted in Table 4 , a strong positive correlation was observed between eGFR, calcium and Hb with HRQoL scores (P < 0.01). Similarly, a negative correlation was observed between ESR, CRP, creatinine and phosphate with HRQoL scores (P < 0.01).
Multilinear regression analyses were performed using stepwise method with the response variable 'PCS' and 'MCS', respectively. Thirteen explanatory variables were included: GFR, age, Hb, TLC, ESR, MAP, BMI, CRP, blood urea, serum creatinine, serum uric acid, serum potassium and blood sugar.
A significant model for PCS emerged (F 8438 ¼185.486, P ¼ 0.000). The regression was a rather good fit; which means that 48.1% of the variance in PCS was explained by the model CVD includes cardiac infarction, congestive heart failure, stroke/TIA and echocardiographic evidence of cardiac disease.). 
Discussion
HRQoL of life assumes increasing importance as a marker of treatment quality in many chronic diseases. 4 Its evaluation allows the quantification of the diseases consequences according to the patient's subjective perception and enables adjustment of medical decisions to their physical, emotional and social needs. The HRQoL in patients with advanced CKD is significantly impaired and is an important indicator of future mortality. Conditions like malnutrition, anemia, cognitive dysfunction, depression, sleep disorders, reduced social interaction, decreased physical and sexual functioning and comorbidities like diabetes and CVD also impair HRQoL in CKD patients. 8, 9 More recently, however, the high mortality rate and prevalence of comorbid conditions even in patients in the earlier stages of CKD have raised concerns that HRQoL could also be low in these patients. However, only limited information is currently available regarding estimates of the relative impact of renal dysfunction on HRQoL and use of predictors of HRQoL as probable targets of intervention. In view of these facts, the study was conducted to evaluate the HRQoL in 200 adult CKD patients. The most common etiology of kidney disease was Diabetes mellitus followed by hypertension, chronic glomerulonephritis and nephrotic syndrome. This spectrum seems to be changing with more recent literature reporting diabetic nephropathy as the commonest cause of ESRD in India. Data from the CKD registry of India reveal that diabetic nephropathy accounts for 31.2% of CKD in India.
10 Our study also revealed that the most common etiology leading to CKD is diabetes mellitus. The HRQoL scores in all dimensions impaired progressively and significantly across the groups with the lowest scores seen in group D. There was progressive impairment of all HRQoL dimensions with decreasing eGFR. Decline in PCS scores was more as compared with MCS scores but difference among groups was significant for both the scores. Similar results were shown by Cruz et al. 11 in 155 patients where quality of life decreased in all stages of kidney disease from stages 1-5. A reduction in physical functioning, physical role functioning and in the physical component summary was observed progressively in the different stages of kidney disease. Older patients performed worse on the physical component summary and better on the mental component summary. 11 In another study carried out by Yadav et al. 12 to assess physical quality of life in CKD patients. The study found that the quality of life of ESRD patients' is compromised as per the Karnofsky rating scale. In the study, 30% of the respondents were having their score as <70%, which means that they would be needing assistance in their daily normal routine. 12 The results showed that CKD has a negative impact on HRQoL. The lowest HRQoL scores were seen in the patients with advanced renal disease. The mean scores of the patients in CKD stages 4 and 5 were lower than among those in earlier stages of CKD 1-3. This confirms the continuous deterioration of HRQoL with more advanced disease stages. PF and role domains are affected even in earlier stages of the disease. This indicates that CKD at late stages seems to imply severe restrictions in daily life function. These results are in accordance to those seen by Lee et al. 13 who evaluated HRQoL in 5555 adults using EQ-5D
questionnaire. It was seen that the proportions of participants who reported problems in each of the five EQ-5D dimensions increased significantly with decreasing eGFR. Participants with an eGFR of 30.0-59.9 ml/min/1.73m 2 had an almost 1.5-fold higher risk of impaired health utility compared with those participants with eGFR ! 90.0 ml/min/1.73m 2 , after adjustment for age, gender, health-related behaviors, socioeconomic and psychological variables, and other comorbidities. 13 Females showed lower scores on PCS as compared with males but there was no difference in MCS scores. Difference in vitality scores was also significantly lower in females as compared with males. But, there was no significant difference in social functioning, role emotional and mental health scores among males and females. Similar results have been in found in a prospective study conducted by Mujais et al.
14 in a cohort of 1186 CKD patients. Physical functioning score declined progressively with more advanced stages of CKD and so did the score for role-physical. Female gender and the presence of diabetes and a history of cardiovascular co-morbidities were also associated with reduced HRQoL. The group aged ! 50 years showed lower scores on PCS and all physical component scales except general health than the younger group, all at a significant level. MCS was also affected significantly by age, although maximum difference was observed in role emotional and social functioning subscale. Patients with MAP ! 100 mmHg had significantly lower PCS, MCS and all other HRQoL dimensions scores as compared with patients with MAP < 100 mmHg. Predictive capacity of MAP on MCS was significantly prominent on multilinear regression analysis.
Our results are in agreement with a cross sectional analysis done by Pagels et al. 15 in 535 patients with CKD stages 2-5 of which 33% were females. Among them 54 patients had CKD stages 2 and 3, 87 patients had CKD stage 4 and 394 patients had CKD stage 5. All HRQoL dimensions deteriorated significantly with CKD stages with the largest differences between the patient groups were seen in 'physical functioning', 'role physical', 'general health' and in physical summary scores. The smallest disparities were seen in mental health and pain. 15 A negative correlation was seen between factors such as eGFR, CVD, diabetes, age and decreased Hb levels and HRQoL. A significant negative correlation was seen between inflammation and eGFR which seem to be important predictors of impaired HRQoL in patients with CKD, followed by reduced Hb and diabetes. This means that patient's health perception is not only related to the renal function, but also to other conditionslike inflammation, CVD and diabetes co morbities commonly seen in patients of CKD. Similar results were in accordance to those seen by Pagels et al. 15 who showed a positive correlation between inflammation, CVD, DM and anemia with poor HRQoL. These findings highlight that key elements concerning HRQoL in CKD patients and indicate that more attention should be paid to conditions such as inflammation and CVD. Besides being an inflammation marker, CRP has also been pointed out as a strong predictor of CVD events. 16 Conditions like inflammation, CVD and diabetes often appear in CKD patients, share both risk factors and some symptoms, and have a negative impact on HRQoL. By screening for these already from an early stage, the possibility for treatment and secondary prevention may increase and contribute to improved well-being and function.
Conclusion
Considering the worldwide growing prevalence of CKD and increasing importance of HRQoL in chronic diseases, improving our knowledge about HRQoL and its predictors in CKD patients is important. The deterioration of HRQoL in CKD is a complex multi-factorial problem which commences early and progress with the stage of disease. There is a need to develop strategies to accurately identify 'high risk' subjects who may benefit from preventive measures before complications occur. Early assessment of key components of HRQoL early in disease course will help to identify high risk subjects in whom modifying these predictors may help in providing active and healthy life for CKD patients.
Limitation of study
The variables depression, anxiety and stress are usually negatively associated with the adherence to treatment, thus indicating that improving emotional states could be a factor to therapeutic compliance.
